VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2021 | Novel immunotherapy combinations in Hodgkin lymphoma

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses novel immunotherapy approaches currently being evaluated in Hodgkin lymphoma. Pembrolizumab in combination with gemcitabine-based chemotherapy or the ifosfamide, carboplatin, etoposide (ICE) regimen is a promising salvage therapy, and pembrolizumab with doxorubicin, vinblastine, and dacarbazine (AVD) is another potential regimen for frontline therapy. Nivolumab and ruxolitinib is an additional combination that may sensitize patients with relapsed/refractory Hodgkin lymphoma to immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Transcript (edited for clarity)

So novel immunotherapy approach, as I said, is combination of pembrolizumab with either ICE chemotherapy or gemcitabine-based chemotherapy, for salvage treatment of classic Hodgkin lymphoma. Pembrolizumab in combination with AVD, AVD is the multi-agent chemotherapy used for frontline treatment of Hodgkin lymphoma. And it’s been used for several years. And now, we are combining pembrolizumab to see if that improves outcome...

So novel immunotherapy approach, as I said, is combination of pembrolizumab with either ICE chemotherapy or gemcitabine-based chemotherapy, for salvage treatment of classic Hodgkin lymphoma. Pembrolizumab in combination with AVD, AVD is the multi-agent chemotherapy used for frontline treatment of Hodgkin lymphoma. And it’s been used for several years. And now, we are combining pembrolizumab to see if that improves outcome. And it has very excellent results.

Some of the efforts are also towards treating these patients who progress after immunotherapy. So that includes combining immunotherapy with another agent that sensitizes the lymphoma to immunotherapy. And so there are a couple of trials, nivolumab plus ruxolitinib in relapse or refractory Hodgkin lymphoma. Or nivolumab plus, sorry, pembrolizumab plus vorinostat in relapse or refractory classic Hodgkin lymphoma. They are also being presented at ASH. So those are the novel combinations.

 

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter